For providers

Your COPD Patient on LABA-LAMA May Have Asthma

October 29, 2026

Editorial illustration for the article "Your COPD Patient on LABA-LAMA May Have Asthma"

A clinical brief for referring providers — week 1 of a 4-part series on asthma-COPD overlap.

A question before the clinical note: A 63-year-old man with a 35 pack-year history and childhood asthma: post-BD FEV1/FVC 0.59, FEV1 54% predicted, blood eosinophils 460/μL, FeNO 48 ppb. He is on a LABA-LAMA inhaler only and had two exacerbations last year. What is the most appropriate next step?

a) Continue LABA-LAMA and reassess in 3 months b) Add an ICS — step to ICS-LABA-LAMA c) Start maintenance oral prednisone d) Switch to LAMA monotherapy e) Start roflumilast

That patient is common. Asthma-COPD overlap — ACO — describes persistent airflow limitation with clinical features of both diseases. In many cohorts it is roughly 25% of COPD patients and about 20% of asthma patients.

It is a descriptive label, not a single disease, and there is no consensus definition: prevalence runs from 0.9% to 11.1% of the general population depending on the criteria used. GINA 2026 has moved away from ACO as a diagnosis. What replaced it is a simpler question — are asthma features present? — because that answer decides whether ICS is mandatory.

The syndromic approach, GINA and GOLD 2026

Highly likely asthma — ICS-containing therapy

Features of both — ICS-containing therapy is essential — treat as asthma, for safety

Likely COPD — LABA-LAMA per GOLD; avoid high-dose ICS and routine maintenance OCS

The safety rule: when any asthma feature is present, never give LABA or LAMA without an ICS. ICS-containing therapy is what reduces the risk of severe exacerbations and death.

One list worth pulling this month

Pull your COPD patients on LABA-LAMA without an ICS, and look for any feature of the asthma component:

Asthma diagnosed before age 40, often in childhood

Blood eosinophils above 300/μL, or above 5%

FeNO above 35–50 ppb

Atopy, perennial allergic rhinitis, or elevated IgE

Variable symptoms, or reversibility above 12% and above 200 mL

Where asthma features are present, add ICS where indicated. Document blood eosinophils and FeNO while you are there — they predict ICS responsiveness, and they are the numbers the next decision rests on.

Refer the patient who does not fit either box

When the features are mixed and the answer is not obvious, the Chest & Sleep Team will work it up with you.

Call (847) 860-7250.

Sources: GINA 2026; GOLD 2026; Leung & Sin, Chest 2022; Mekov et al., Int J COPD 2021.

Abbreviations: ACO, asthma-COPD overlap. ICS, inhaled corticosteroid. LABA, long-acting beta-agonist. LAMA, long-acting muscarinic antagonist. OCS, oral corticosteroid. BD, bronchodilator. FEV1/FVC, air forced out in the first second divided by the total. FeNO, fractional exhaled nitric oxide, a breath test for type-2 airway inflammation.

The answer

Add an ICS. Childhood asthma, high eosinophils and high FeNO are asthma features, and when asthma features are present ICS-containing therapy is mandatory — LABA or LAMA should never be used without it. Maintenance OCS and roflumilast are not first-line here, and stepping down to monotherapy is unsafe.